|
|
Post by oldfishtowner on Apr 2, 2019 7:43:57 GMT -5
it cost now 5 $ a day and Offer will expire on December 31, 2019. Does the price increase mean that the program has reached or exceeded its original goal of 1000 patients? |
|
|
|
Post by mnholdem on Apr 2, 2019 7:45:18 GMT -5
“Prescription is available in 3 month fills for additional savings.”
|
|
|
|
Post by peppy on Apr 2, 2019 7:46:00 GMT -5
|
|
|
|
Post by agedhippie on Apr 2, 2019 7:47:35 GMT -5
The offer has changed. The one month price has increased, but a cheaper 3 monthly option has been added which makes sense because that's how insurers usually dispense insulin. It looks like this is the price adjustment at the end of the trial period so my guess is that this is the new price going forward.
- $150 for a one month fill of the 90 count pack of 4, 8 or 12 Unit Afrezza Cartridges or $250 for a one month fill of 180 count Afrezza Cartridges.
- $299 for a 3 month fill of the 90 count pack of 4, 8 or 12 Unit Afrezza Cartridges or $599 for 3 month fill of the combination pack of 180 count Afrezza Cartridges.
That makes the monthly price of three month fills $100 per month for the 90 count, and $200 per month for the 180 count.
The old price was $120, and $199 per month respectively.
|
|
|
|
Post by ltta on Apr 2, 2019 7:48:16 GMT -5
Where did you find this info? Please provide a link. The link above still mentions $4 a day. No PR, no link from Afrezza.com, no link from the Mannkind website. How are PWD supposed to find this Insulin Savings program? <iframe style="position: absolute; width: 16.899999999999977px; height: 4.840000000000003px; z-index: -9999; border-style: none;left: 15px; top: -5px;" id="MoatPxIOPT1_80159278" scrolling="no" width="16.899999999999977" height="4.840000000000003"></iframe> <iframe style="position: absolute; width: 16.9px; height: 4.84px; z-index: -9999; border-style: none; left: 792px; top: -5px;" id="MoatPxIOPT1_46186778" scrolling="no" width="16.899999999999977" height="4.840000000000003"></iframe> <iframe style="position: absolute; width: 16.9px; height: 4.84px; z-index: -9999; border-style: none; left: 15px; top: 181px;" id="MoatPxIOPT1_6372249" scrolling="no" width="16.899999999999977" height="4.840000000000003"></iframe> <iframe style="position: absolute; width: 16.9px; height: 4.84px; z-index: -9999; border-style: none; left: 792px; top: 181px;" id="MoatPxIOPT1_65264409" scrolling="no" width="16.899999999999977" height="4.840000000000003"></iframe> |
|
|
|
Post by sportsrancho on Apr 2, 2019 8:58:38 GMT -5
No PR, no link from Afrezza.com, no link from the Mannkind website. How are PWD supposed to find this Insulin Savings program? <iframe style="position: absolute; width: 16.899999999999977px; height: 4.840000000000003px; z-index: -9999; border-style: none;left: 15px; top: -5px;" id="MoatPxIOPT1_80159278" scrolling="no" width="16.899999999999977" height="4.840000000000003"></iframe> <iframe style="position: absolute; width: 16.9px; height: 4.84px; z-index: -9999; border-style: none; left: 792px; top: -5px;" id="MoatPxIOPT1_46186778" scrolling="no" width="16.899999999999977" height="4.840000000000003"></iframe> <iframe style="position: absolute; width: 16.9px; height: 4.84px; z-index: -9999; border-style: none; left: 15px; top: 181px;" id="MoatPxIOPT1_6372249" scrolling="no" width="16.899999999999977" height="4.840000000000003"></iframe> <iframe style="position: absolute; width: 16.9px; height: 4.84px; z-index: -9999; border-style: none; left: 792px; top: 181px;" id="MoatPxIOPT1_65264409" scrolling="no" width="16.899999999999977" height="4.840000000000003"></iframe> Offer will expire on December 31, 2019 |
|
|
|
Post by mannmade on Apr 2, 2019 9:49:12 GMT -5
Couple of questions come to mind...
1. As many have asked, has the original offer to 1,000 been reached? Would be nice to announce it has and that was so successful mnkd wants to extend fr rest of year.
2. How many are signing up and at what rate?
3. Given current rate of retention of refills, the real question is what can mnkd expect for retention? Are they dong anything differently to ensure greater retention?
4. Is this program effecting weekly symphony scripts/cannabalizing retail?
|
|
|
|
Post by brotherm1 on Apr 2, 2019 10:09:19 GMT -5
5. Is the program bringing in the same net revenue per script as the scripts covered with insurance? (e.g. around 50% or so of the per script revenue listed by Symphony?)
|
|
|
|
Post by mnkdfann on Apr 30, 2019 23:30:28 GMT -5
I could be mistaken, but I think Eagle has added some new options: www.eaglepharmacy.com/drug/afrezza-rThe price you pay: $150 for a quantity of 90 cartridges (1 month supply) of Afrezza through MannKind's Afrezza Patient Direct program $250 for a quantity of 180 cartridges (1 month supply) of Afrezza through MannKind's Afrezza Patient Direct program $299 for a quantity of 90 cartridges (3 month supply) of Afrezza through MannKind's Afrezza Patient Direct program $599 for a quantity of 180 cartridges (3 month supply) of Afrezza through MannKind's Afrezza Patient Direct program |
|
|
|
Post by parrerob on May 3, 2019 13:38:08 GMT -5
Couple of questions come to mind... 1. As many have asked, has the original offer to 1,000 been reached? Would be nice to announce it has and that was so successful mnkd wants to extend fr rest of year. 2. How many are signing up and at what rate? 3. Given current rate of retention of refills, the real question is what can mnkd expect for retention? Are they dong anything differently to ensure greater retention? 4. Is this program effecting weekly symphony scripts/cannabalizing retail? Answer to point 4 is Yes as they are not counted in Symphony. The real question number 4 should be how much the DTC affect Symphony data..... also are there patients already with Afrezza who switched to the dtc? Really hope next week to know somthing more at least on question 1 and 2 |
|
|
|
Post by peppy on May 3, 2019 13:46:31 GMT -5
Couple of questions come to mind... 1. As many have asked, has the original offer to 1,000 been reached? Would be nice to announce it has and that was so successful mnkd wants to extend fr rest of year. 2. How many are signing up and at what rate? 3. Given current rate of retention of refills, the real question is what can mnkd expect for retention? Are they dong anything differently to ensure greater retention? 4. Is this program effecting weekly symphony scripts/cannabalizing retail? Answer to point 4 is Yes as they are not counted in Symphony. The real question number 4 should be how much the DTC affect Symphony data..... also are there patients already with Afrezza who switched to the dtc? Really hope next week to know somthing more at least on question 1 and 2 Can I use my insurance? : No, insurance can not be applied to this program. www.eaglepharmacy.com/drug/afrezza-r |
|
|
|
Post by mnkdfann on May 3, 2019 15:11:34 GMT -5
Couple of questions come to mind... 1. As many have asked, has the original offer to 1,000 been reached? Would be nice to announce it has and that was so successful mnkd wants to extend fr rest of year. 2. How many are signing up and at what rate? 3. Given current rate of retention of refills, the real question is what can mnkd expect for retention? Are they dong anything differently to ensure greater retention? 4. Is this program effecting weekly symphony scripts/cannabalizing retail? Answer to point 4 is Yes as they are not counted in Symphony. The real question number 4 should be how much the DTC affect Symphony data..... also are there patients already with Afrezza who switched to the dtc? Really hope next week to know somthing more at least on question 1 and 2 Agree with what you wrote, except I think it is the case that the scripts in question are not REPORTED to Symphony. It is (I think) possible that Symphony might be imputing estimates (hence counting them in some fashion) for unknown scripts, as it does for other missing data. Not saying this is the case, just saying I think we don't know for certain. Just MHO. |
|
|
|
Post by sportsrancho on May 3, 2019 15:28:01 GMT -5
My guess is there’s no way for symphony to estimate anything....it’s a new program, and I’m thinking we have at least 500 people using eagle.
|
|
|
|
Post by ktim on May 3, 2019 18:42:58 GMT -5
Answer to point 4 is Yes as they are not counted in Symphony. The real question number 4 should be how much the DTC affect Symphony data..... also are there patients already with Afrezza who switched to the dtc? Really hope next week to know somthing more at least on question 1 and 2 Agree with what you wrote, except I think it is the case that the scripts in question are not REPORTED to Symphony. It is (I think) possible that Symphony might be imputing estimates (hence counting them in some fashion) for unknown scripts, as it does for other missing data. Not saying this is the case, just saying I think we don't know for certain. Just MHO. I believe they would estimate, but they very likely aren't basing it taking the existence of this program into account. So if there is a meaningful number then they are likely significantly under reporting. Big question is how significant it has been. |
|
|
|
Post by ilovekauai on May 4, 2019 14:48:04 GMT -5
I just went to the insuling savings website and looked up endos who're willing to prescribe Afrezza in my area. Interestingly enough, my endo was included in the list yet when I saw her last week, she showed zero interest in prescribing me Afrezza and actually talked it down as I've mentioned before here in other posts. How can this possibly be? How can she be listed as a provider, be so restitant to prescribing, and actually talk doen the product? This makes no sense whasoever. I'm very confused about this. Why is she lsited there in the first place?
|
|
